A Successful Treatment for Stage IIi c Gastric Cancer with Low Cardiac Function Using S-1 plus Oxaliplatin (SOX) as a Neoadjuvant Chemotherapy
Terashima, T.; Kawamoto, S.; Maekawa, K.; Kuroki, N.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(12): 1892-1894
2017
ISSN/ISBN: 0385-0684 PMID: 29394811 Document Number: 692624
A 83-year-old female, with oppression in her chest, was subjected to type 2 advanced gasteric cancer in esophagogastric junction. Examinations revealed Stage III c of cT4, cN2, cM0. For adopting neoadjuvant chemotherapy, S-1 plus CDDP was not on the list, but S-1 plus oxaliplatin (SOX) was, because massive load of infusion along with the chemotherapy was not appropriate for the patient with low cardiac function. After 2 courses of SOX, the primary tumor as well as metastatic lymph nodes were shown with marked reduction in size by CT scan, which enabled total gastrectomy with D2 lymphadenectomy to be performed as a curative resection, leading to patient living with no recurrence more than 3 years. SOX was considered as one of safe neoadjuvant agent for gastric cancer combined with low cardiac function.